News

ELCC: Phase I study of CO-1686 in patients with EGFR mutated recurrent, advanced NSCLC

31 Mar 2014
ELCC: Phase I study of CO-1686 in patients with EGFR mutated recurrent, advanced NSCLC

Evaluation of an irreversible, mutant-selective inhibitor of EGFR mutations

CO-1686 has demonstrated a good tolerability and promising efficacy against T790M epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).

To read the rest of this story visit the ESMO site.